Schering Corporation, Plaintiff-Appellee-Cross-Appellant v. Home Insurance Company, Defendant-Appellant-Cross-Appellee

712 F.2d 4, 1983 U.S. App. LEXIS 26542
CourtCourt of Appeals for the Second Circuit
DecidedJune 21, 1983
Docket1314, Dockets 83-7056, 83-7102
StatusPublished
Cited by334 cases

This text of 712 F.2d 4 (Schering Corporation, Plaintiff-Appellee-Cross-Appellant v. Home Insurance Company, Defendant-Appellant-Cross-Appellee) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schering Corporation, Plaintiff-Appellee-Cross-Appellant v. Home Insurance Company, Defendant-Appellant-Cross-Appellee, 712 F.2d 4, 1983 U.S. App. LEXIS 26542 (2d Cir. 1983).

Opinion

KAUFMAN, Circuit Judge:

When a motion for summary judgment presents complex legal issues with far-reaching implications, a judge must balance two competing goals. Confronted with the prospect of lengthy pre-trial proceedings that postpone the day of judgment, the district court must conserve judicial resources by promptly resolving those matters in which “no genuine issue as to any material fact” is presented. Fed.R.Civ.P. 56(c). At the same time, justice requires careful consideration of the entire posture of the case so the “drastic device” of summary judgment, Heyman v. Commerce and Industry Co., 524 F.2d 1317, 1320 (2d Cir.1975), is not precipitously imposed.

In its understandable zeal to resolve non-perspicuous issues of interpretation, a district court may at times lose sight of the need for restraint. Justice must be both rapid and fair. Matters which our system of conflict resolution reserves for full exposition at trial may not be consigned to cursory disposition. This Court has on numerous occasions set forth the standards which judges must follow in deciding whether to grant summary judgment. See, e.g., Quinn v. Syracuse Model Neighborhood Corp., 613 F.2d 438, 444-45 (2d Cir.1980); SEC v. Research Automation Corp., 585 F.2d 31, 33 (2d Cir.1978); Home Insurance Co. v. Aetna Casualty & Surety Co., 528 F.2d 1388, 1390 *7 (2d Cir.1976); Héyman v. Commerce and Industry Co., supra, 524 F.2d at 1319-20. Because we believe the court below misapplied these guidelines in the present dispute, we reverse its grant of summary judgment in this declaratory judgment action and remand for further proceedings.

To facilitate understanding of the issues raised for our consideration, we set forth the facts in some detail, mindful that ambiguities must be resolved and reasonable inferences drawn in favor of the party against whom summary judgment is sought. Heyman v. Commerce and Industry Co., supra, 524 F.2d at 1320.

I

This controversy arose from a dispute between Schering Corporation (“Schering”), a drug manufacturer, and its excess liability insurer, Home Insurance Company (“Home”). At stake is Home’s potential liability for untold millions of dollars in payment for claims by plaintiffs who assert injury from Schering’s synthetic estrogen product, dienestrol (“DEN”). The story of DEN is a tragic tale of modern medicine as well as a word of caution to insurers to anticipate potential problems created by unscrutinized standard clauses in policies.

In 1958, Schering commenced the manufacture and distribution of DEN either directly or through a subsidiary. Synthetic estrogens such as DEN and its chemical cousin, the well-known diethylstilbesterol (“DES”), have been prescribed to women since the early 1940’s for a variety of reasons. In particular, DEN was widely administered to patients with high-risk pregnancies for the purpose of preventing miscarriages.

While thousands of doctors were dispensing synthetic estrogens to millions of expectant mothers, Schering and Home entered into an important series of contracts. From August 30, 1966 to February 7, 1976, Schering paid Home over $1,000,000 in premiums for excess liability coverage. Unable to anticipate the tidal wave of controversy, anguish, and, finally, litigation, that would soon inundate the makers and users of both DES and DEN, Schering and its insurer concluded standard-form comprehensive general liability (“CGL”) contracts. The critical provision of this type of policy is the stipulation that the insurer agreed to indemnify the manufacturer for liability when use of its products resulted in personal injury during the policy period. The pertinent language is set forth in the margin. 1

In 1971, an association between synthetic estrogens and clear-cell vaginal adenocarcinoma (a cancer of glandular tissues in the vagina) in daughters of women who had taken DES was reported in the medical literature. Herbst, Ulfelder & Poskanzer, Adenocarcinoma of the Vagina, 284 New England J.Med. 878 (1971). Later that year, the Food and Drug Administration (FDA) proscribed the use of DEN (as well as DES) in the treatment of pregnant women. Although DES and DEN continue to be marketed for purposes other than preventing miscarriages, their deleterious effects on female offspring of women who took the drugs while with child (commonly referred to as “DES daughters”) are well documented. Since the initial study and FDA banning order, maternal ingestion has been associated with adenosis (abnormal presence of glandular epithelial cells or tissue in the vagina or cervix), structural abnormalities of the cervix and vagina, surgical interventions such as vaginectomies, and a host of other afflictions (infertility, anxiety, embarrassment, mental anguish, and other psychological sequela).

*8 Filial redress for injuries suffered while in útero promises to be expensive for both manufacturers and insurers. The instant case arose because the settlement of a single DES daughter action exhausted Schering’s primary liability of $1 million for the year 1974. Numerous other actions against Schering and its fellow manufacturers are pending. See Brief of Amici Curiae The Upjohn Company, Abbott Laboratories, Emons Industries, Inc. and E.R. Squibb & Sons, Inc. When Schering turned to its secondary liability insurer, Home, for further indemnification, the parties disagreed over whether the terms of the policies required Home to pay for these injuries. Insured and insurer professed divergent views on when DEN injury or damage “occurred” —before 1966, when pregnant mothers consumed the substance, or later, during the policy period, when the unfortunate daughters discerned the extent of the harm innocently inflicted on them by well-meaning mothers and their physicians. Predictably, litigation followed.

II

Schering initially sought a declaratory judgment pursuant to 28 U.S.C. § 2201 for a statement of its rights under the insurance policies. On May 6, 1980, the trial court approved a stipulation in which the parties agreed to dismissal of Schering’s complaint without prejudice. The action proceeded on counterclaims filed on January 16, 1980 by Home. The litigation was to resolve, inter alia, the issue whether Home was obligated to defend or indemnify Schering for any loss from prenatal use of DEN “which resulted, was discovered or became manifest” during the policy period. Schering’s motion for summary judgment was filed November 10, 1980.

Appellee’s original contention was that the proper interpretation of the key words “results in personal injury ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spacek v. MARKETWATCH, INC.
420 F. Supp. 2d 303 (S.D. New York, 2006)
Katt v. Titan Acquisitions, Inc.
244 F. Supp. 2d 841 (M.D. Tennessee, 2003)
Bazile v. City of New York
215 F. Supp. 2d 354 (S.D. New York, 2002)
Blazek Ex Rel. Blazek v. United States
135 F. Supp. 2d 978 (S.D. Iowa, 2001)
Schweizer v. Mulvehill
93 F. Supp. 2d 376 (S.D. New York, 2000)
In Re Rockefeller Center Properties
241 B.R. 804 (S.D. New York, 1999)
In Re Crystal Apparel, Inc.
220 B.R. 816 (S.D. New York, 1998)
Hassett v. Altai, Inc. (In Re CIS Corp.)
214 B.R. 108 (S.D. New York, 1997)
Monaco v. CIS Corp. (In Re CIS Corp.)
206 B.R. 680 (S.D. New York, 1997)
DeFalco v. Dirie
923 F. Supp. 473 (S.D. New York, 1996)
In Re Finley, Kumble, Wagner, Heine, Underberg
194 B.R. 728 (S.D. New York, 1995)
In Re Houbigant, Inc.
182 B.R. 958 (S.D. New York, 1995)
Calzaturificio Rangoni S.P.A. v. United States Shoe Corp.
868 F. Supp. 1414 (S.D. New York, 1994)
In Re Finley, Kumble, Wagner, Heine, Underberg
192 B.R. 342 (S.D. New York, 1994)
Fontaine v. Ryan
849 F. Supp. 190 (S.D. New York, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
712 F.2d 4, 1983 U.S. App. LEXIS 26542, Counsel Stack Legal Research, https://law.counselstack.com/opinion/schering-corporation-plaintiff-appellee-cross-appellant-v-home-insurance-ca2-1983.